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Abstract
Background: Cisplatin (DDP)-based chemotherapy is the common first-line therapy for lung cancer. However, their
efficacy is often limited by primary drug resistance and/or acquired drug resistance. The aim of this study was to
investigate the function of miRNA-146a (miR-146a) in DDP-resistant non-small cell lung cancer (NSCLC), as well as
the underlying mechanisms.
Methods: The effect of overexpression of miR-146a and/or knockdown of cyclin J (CCNJ) in A549/DDP and SPC-A1/
DDP cells were investigated as follows. The cellular sensitivity to DDP, cell apoptosis, cell cycle and cell mobility were
detected by CCK-8, flow cytometry, hoechst staining and cell invasion/migration assay, respectively. The effects
of miR-146a overexpression in NSCLC resistant cells were further analyzed in a nude mouse xenograft model.
Results: Overexpression of miR-146a and/or knockdown of CCNJ significantly increased the sensitivity to DDP
in A549/DDP and SPC-A1/DDP cells compared to NC group via arresting cell cycle, enhancing cell apoptosis,
inhibiting cell viability and motility in vitro and in vivo. Furthermore, miR-146a could specially degrade the mRNA of
CCNJ, as examined by dual luciferase report assay.
Conclusion: The study indicates a crucial role of miR-146a in the development of acquired drug resistance to DDP in
NSCLC cells. Further understanding of miR-146a mediated crosstalk networks may promote the clinical use of miR-146a
analogue in NSCLC therapy.
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Background
Lung cancer is one of the most common malignant
tumors and has one of the highest mortality rats world-
wide [1], 80–85% of which are non-small cell lung can-
cer (NSCLC) [2]. The cis-diamminedichloroplatinum (II)
(cisplatin, cDDP, DDP)-based chemotherapy is the com-
mon first-line therapy for clinical treatment of various
malignant tumor, including lung cancer for more than
40 years [3–5]. Unfortunately, its efficacy is often limited
due to the development of resistance to DDP-based
therapy [2, 6]. Although more and more studies have
described the resistance to DDP in NSCLC, the under-
lying mechanisms are not fully elucidated at present
[7–10]. Therefore, a better understanding of these
mechanisms of DDP resistance in NSCLC will aid the
clinicians to improve NSCLC treatment and develop
new targets for tumor chemoresistance.
MicroRNAs (miRs) are a superfamily of small non-
coding RNAs with single-stranded 19–25 nucleotides,
which could bind to the 3′-untranslated region (3′-UTR)
of their targeted genes, resulting in mRNAs cleavage and/
or translational repression [11, 12]. Functionally, miRs
have been widely involved in the regulation of various bio-
logical processes, including embryonic development, cell
cycle, differentiation, proliferation, migration, and apop-
tosis [13–15]. In addition, increasing studies have shown
that dysregulation of miRNAs are associated with the
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chemoresistance in the initiation and progression of can-
cers [16–30]. Recently, miR-146a has been demonstrated
to be up-regulated in various cancers, such as cervical
cancer [31] and thyroid cancer [32, 33]. Moreover, miR-
146a levels have therapeutic potential to suppress invasion
and migration capacity in breast cancer [34] and pancre-
atic cancer [35]. However, there have been no published
data regarding the roles of miR-146a in drug resistance of
NSCLC cells.
In this study, we aimed to investigate the role of miR-
146a in the chemosensitivity of NSCLC cells to DDP by
analyzing its function in vitro and vivo. Combined with
our previously data that miR-146a were significantly down-
regulated in the A549/DDP cells compared with A549 cells
(data was not shown), we further found that up-regulation
of miR-146a markedly inhibited the migration, invasion
and reversed the chemoresistance of NSCLC cells partially
through targeting CCNJ. Our findings might provide a
new therapeutic strategy for NSCLC patients with acquired
resistance to DDP.
Methods
Cell lines and reagents
Human embryonic kidney 293T cells (Cat no. SCSP-502)
were obtained from the Cell Bank of Chinese Academy
of Science (Shanghai, China) and maintained in DMEM
medium containing 10% FBS. A549 and A549/DDP cells
were purchased from BioLeaf Biotech (Shanghai, People’s
Republic of China). SPC-A and SPC-A1/DDP cells were
obtained from Department of Molecular Biology and
Biochemistry (Nanjing Medical University). A549 and
SPC-A1 cells were maintained in RPMI-1640 (Hyclone,
Cat no. SH30243.01B) supplemented with 10% FBS (BI,
Cat no. 04-001-1A). A549/DDP and SPC-A1/DDP cells
were cultured in containing 10% FBS RPMI-1640 sup-
plemented with 1 μg/ml DDP (selleck, Cat no. S7786).
All cells were cultured at 37 °C in a humidified incubator
containing 5% CO2. To avoid the effects of the drugs, re-
sistant cell lines were cultured in a drug-free medium for
1 week prior to further experiments.
Construction of A549/DDP and SPC-A1/DDP stable cells
clones with miR-146a overexpression
MiR-146a (the full-length pri-miR-146a) were cloned into
lenti-miR overexpression plasmid PGC-Lv (Genechem,
Cat no. GV235). MiR-146a and control (NC) plasmid
were packaged with lenti-packaging plasmid mix (pHelper
1.0, and pHelper 2.0) in a 293T packaging cell line.
Viruses were concentrated and purified using ultracentri-
fugation. Transfection was performed with Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instruction. Stably cells clones were selected
with puromycin (1 μg/ml) 48 h after lentiviruses transfec-
tion, and individual clone was isolated and maintained in
a medium containing puromycin (0.5 μg/ml). The expres-
sion of miR-146a was confirmed by real-time quantitative
PCR (RT-qPCR).
siRNA and transfection
A small interfering RNA (siRNA) targeting CCNJ
(siCCNJ) with the sequences (sense 5′-UGGAUUUGUAC
CAUUCUUCUGdtdt-3′ and anti-sense 5′-GAAGAAUG-
GUACAAAUCCAAGdtdt-3′) and non-targeting siRNA
(NC) were purchased from RiboBio (Guangzhou, China).
For cell transfection, A549/DDP and SPC-A1/DDP cells
were transfected with siCCNJ or NC at a final concentra-
tion of 50 nM using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) following the manufacturer’s instruc-
tions. Silencing efficiency of CCNJ was determined at
mRNA and protein levels by RT-qPCR and Western
blotting, respectively.
CCK-8 assay
The transfected cells were seeded into 96-well culture
plates at a density of 5000 cells per well. After culture
for 12 h, cells were added serially diluted DDP (0, 2, 4, 6,
8 μg/ml) and incubated for 48 h. A total of 10 μl CCK-8
solution was added to each well after treatment, followed
by another 1–2 h incubation. Optical density value at
450 nm (OD450) was detected using the New Epoch™ 2
Epoch Microplate Spectrophotometer (Biotek, CA, USA).
The IC50 value was calculated by nonlinear regression
analysis with GraphPad Prism 5.0 (GraphPad Software
Inc., San Diego, CA, USA), using the dose-response with
variable slope function.
RT-qPCR assay
Total cellular or tissular RNA was extracted using TRI-
zol® reagent (Invitrogen, Cat no.15596-018). Approxi-
mately 1 μg of extracted total RNA sample was reverse
transcribed into cDNA using PrimeScript™ RT reagent
Kit (Takara, Otsu, Japan) following the manufacturer’s
protocol. Quantification of miRNA or mRNA was per-
formed using Bestar™ qPCR Master Mix (SYBR Green)
according to the manufacturer’s instructions. RT-qPCR
primers used were as follow: miR-146a sense, 5′-GCGA
GGTCAAGTCACTAGTGGT-3′ and antisense, 5′-CGA
GAAGCTTGCATCACCAGAGAACG-3′; U6 sense, 5′-
CTCGCTTCGGCAGCACA-3′ and antisense, 5′-AACG
CTTCACGAATTTGCGT-3′; CCNJ sense, 5′-TGTCC
GTCAGAACCCATGC-3′ and antisense, 5′-AAAGTC-
GAAGTTCCATCGCTC-3′; GAPDH sense, 5′-GCACC
GTCAAGGCTGAGAAC-3′ and antisense, 5′-TGGT
GAAGACGCCAGTGGA-3′. The cycling conditions
were as follow: initial denaturation at 95 °C for 60 s, 95 °C
for 5 s, 58 °C for 20 s, 40 cycles. Data analysis was per-
formed using the 2-ΔΔCt method.
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Western blot
The cells were harvested and lysed using the mammalian
protein extraction reagent RIPA (Beyotime, Beijing, China).
Total protein concentration of the lysate was measured by
BCA Protein Assay Kit (Pierce Biotechnology, Cat no.
23235). Approximately 50 μg proteins extraction in each
lane were separated on 10% SDS-PAGE and transferred
onto a PVDF membrane (BioRad, Cat no.162-0177). The
membrane was incubated with primary antibodies over-
night at 4 °C, followed by incubation of horseradish-
peroxidase (HRP) conjugated goat anti-rabbit IgG anti-
body (Santa Cruz, Cat no. SC-2054; 1:5000 dilution).
Signals intensity were measured by the ECL-PLUS/Kit
(Amersham, Cat no. RPN2132) following the manufac-
turer’s protocol. The blots were quantified by densitom-
etry using Quantity One software (Bio-Rad, CA, USA).
GAPDH antibody was used as an internal control. The
primary antibodies were as follow: rabbit anti-CCNJ (Cat.
no. ab138561, 1:1000 dilution), P-gp (Cat. no. ab103477,
1:1000 dilution), MRP1 (Cat. no. ab99531, 1:1000 dilu-
tion), MVP/LRP (Cat. no. ab97311, 1:1000 dilution), P53
(Cat. no. ab31333, 1:1000 dilution), cleaved caspase-3
(Cat. no. ab2302, 1:200 dilution) were provided by Abcam
(MA, USA).
Cell cycle and apoptosis using flow cytometry
For cell cycle analysis, cells were harvested, washed with
ice-cold PBS and then fixed with 70% ethanol (v/v) over-
night at −20 °C. Fixed cells were washed with ice-cold
PBS twice and then resuspended in PBS containing PI
(50 μg/ml)/RNase A (50 μg/ml) for 10 min. For cell
apoptosis analysis, cells were double stained with
Annexin V-FITC (1 μg/ml) and PI (1 μg/ml). Finally,
both cell cycle and apoptosis analyzed using a FACScan
instrument (Becton Dickinson, Mountain view, CA, US)
equipped with CellQuest software (Becton Dickinson,
Mountain view, CA, US).
Hoechst staining assay
Cells were cultured in six-well plates for 48 h after
transfection and added Hoechst 33342 (1 μg/ml, Sigma,
USA) for 10 min. After washed with PBS, the changes in
nuclear morphology were observed with fluorescence
microscopy.
In vitro transwell assays
The cell motility was assessed by transwell migration
chambers (8.0 μm pore size; 6.5 mm diameter, Corning)
following manufacture’s instruction. For cell migration,
approximately 5 × 104 transfected cells were seeded into
upper chambers in 600 μl serum free medium. For cell
invasion assay, 0.2.mg/ml MatrigelTM Basement Mem-
brane Matrix (BD, Cat. no. 356234) was coated the
upper chamber. The Matrigel was allowed to solidify at
37 °C overnight. After solidification, 5 × 104 transfected
cells in serum-free medium were seeded into the upper
chamber. The lower transwell chamber contained 10%
FBS RPMI-1640 was used as achemoattractant. After
cultured for 24 h, the cells were removed from the upper
surface and then fixed in 4% paraformaldehyde and fi-
nally stained with 0.1% crystal violet solution. For quan-
tification, the migratory cells and invasion cells were
counted under a microscope in five random fields. Each
experiment was carried out in triplicate and the mean
values were presented.
Dual-luciferase reporter assay
A CCNJ-WT (wild type of miR-146a binding site in 3′-
UTR of CCNJ) and CCNJ-MUT (miR-146a binding site
in 3′-UTR of CCNJ) luciferase reporter was constructed
by Genechem (Shanghai, China). Briefly, the wild type
and mutated of 3′-UTR sequence of CCNJ predicted to
interact with miR-146a were synthesized by Genechem,
and cloned into psi-CHECK2 vector (Promega, Madison,
WI, USA). The constructs were sequenced and named
as CCNJ/3′-UTR-WT or CCNJ/3′-UTR-MUT. For re-
porter assays, 0.05 μg firefly luciferase reporter plasmid
psi-CHECK2 and 0.01 μg renilla luciferase (internal ref-
erence vector) was co-transfected into 293T cells which
transfected with lentivirus containing miR-146a or NC
using Lipofectamine 2000 in 96-well plates. Luciferase
activity (fluorescence intensity) was determined using
fluorophotometer 36 h after transfection.
Xenograft transplantation and in vivo chemosensitivity
assay
A549 cells and A549/DDP cells transfected with miR-
146a or NC (5 × 106 in 0.2 ml of PBS) were suspended
in Matrigel mixture and were subcutaneously injected
into BALB/c nude mice (Nu/Nu, female, 4–6 weeks old,
n = 8/group), which were purchased from Sun Yat-sen
University (Guangdong, China) and maintained under
pathogen-free conditions. After one week, mice were
treated with DDP (3.0 mg/kg body weight; per 3 days).
Tumor volume was monitored for 4 weeks and mea-
sured per 3 or 4 days. The tumor volume formed was
calculated by the following formula: Volume = (Length ×
width2) × 0.5. Then mice were euthanized by cervical
dislocation. Tumors were harvested and divided into
two parts: half of each tumor was frozen in liquid nitro-
gen and stored at −80 °C for RT-qPCR and Western
blotting analysis. The other half was fixed in 4% parafor-
maldehyde for TUNEL assay, H&E and IHC analysis as
previously described [30, 36].
Bioinformatic and statistical analysis
Online miRNA databases (miRBase, TargetScan, MiRanda,
and PicTarget) were used to predict the target gene of
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miR-146a. The Graph pad prism 5.01 software system was
used for statistical analysis. Data are expressed as the
mean ± SD. All experiments were repeated three times.
The statistical significance of the results between each
group was evaluated using one-way ANOVA or t-test.
Differences were considered significant at *p < 0.05,
**p < 0.01, and ***p < 0.001.
Results
Overexpression of miR-146a enhanced the sensitivity
ofA549/DDP and SPC-A1/DDP cells to DDP
Our previously micro-array data have shown that miR-
146a were down-regulated in the A549/DDP cell com-
pared with A549 cell (data was not shown). To deeply
investigate the roles of miR-146a in the DDP resistance
in DDP-resistant NSCLC cells, the stably overexpressed
miR-146a cell lines were established by transfecting
miR-146a into A549/DDP and SPC-A1/DDP cells, re-
spectively. As shown in Fig. 1a, miR-146a expression
was significantly increased in A549/DDP/miR-146a and
SPC-A1/DDP/miR-146a cells compared with A549/
DDP/NC and SPC-A1/DDP/NC. CCK-8 assay was then
performed to determine the effects of miR-146a on cell
viability of A549/DDP and SPC-A1/DDP cells when ex-
posed to DDP treatment. The IC50 values for DDP
were decreased from 7.69 ± 0.733 μg/ml in A549/DDP/
NC to 3.76 ± 0.388 μg/ml in A549/DDP/miR-146a cells.
Similarly, overexpression of miR-146a significantly re-
duced the IC50 values from 5.48 ± 0.641 μg/ml to 2.41
± 0.339 μg/ml in SPC-A1 cells (Fig. 1b), which indi-
cated that overexpression of miR-146a could partially
reverse the DDP-resistant NSCLC cells. Next, we ana-
lyzed the effects of miR-146a on cell cycle and apop-
tosis of A549/DDP and SPC-A1/DDP cells by flow
cytometry. Compared with A549/DDP/NC and SPC-
A1/DDP/NC cells, the percentage of G0/G1 phase was
increased and S phase was decreased in both A549/DDP/
miR-146a and SPC-A1/DDP/miR-146a cells under 1 μg/
ml DDP treatment (Fig. 1c). Also, miR-146a could signifi-
cantly increase apoptosis rate of A549/DDP (34.5 vs
12.5%) or SPC-A1/DDP (25.2 vs12.3%) cells compared
with control group under 1 μg/ml DDP treatment
(Fig. 1d, p < 0.001). Consistantly, hochest 33342 staining
revealed obviously decrease in the nuclei of live cells
(blue color) (Fig. 1e). Collectively, up-regulation of
miR-146a could reverse the chemo-resistance to DDP
in NSCLC cells by inducing cell-cycle arrest in G0/G1
phase and apoptosis. In addition, we assessed cell inva-
sion and migration through a transwell assay. As shown
in Fig. 2a and b, overexpression of miR-146a signifi-
cantly impaired the invasion and migration ability of
A549/DDP or SPC-A1/DDP cell under 1 μg/ml DDP
treatment (p < 0.001).
CCNJ was identified as a functional target of miR-146a
As we know, miRs exert their function by affecting their
target genes expression. Thus, the target genes of miR-
146a were predicted through four publicly available web
(miRBase, TargetScan, MiRanda, and PicTarget), and
CCNJ was selected as a putative target (Fig. 3a). To dir-
ectly address whether miR-146a binds to the 3′-UTR of
CCNJ mRNA, we constructed luciferase reporters carry-
ing the 3′-UTR with the putative miR-146a binding sites
for CCNJ mRNA. Correspondingly, we also generated a
mutant reporter vector which contains the CCNJ3′-
UTR with a mutation at the putative miR-146a binding
site. Dual-luciferase reporter assay showed that miR-
146a significantly inhibited the relative luciferase activity
of the report vector which contains the 3′-UTR of CCNJ
construct. In contrast, no change of luciferase activity
was observed in cells transfected with the mutant 3′-
UTR of CCNJ constructs (Figure3B). It suggests that
miR-146a might have a target site in the 3′-UTR of
CCNJ mRNA. We next determined whether overexpres-
sion of miR-146a could downregulate CCNJ expression.
As shown in Fig. 3c and d, the expression of CCNJ (both
mRNA and protein level) was significantly lower in miR-
146a overexpressed cells than that in NC group by RT-
qPCR and Western blot. These results further suggest
that CCNJ is a direct target of miR-146a in NSCLC cells,
and miR-146a may negatively regulate the expression of
CCNJ. Furthermore, we found that drug-resistance-
associated proteins (P-gp, MRP1 and LRP) and P53 were
decreased but apoptosis-related protein (cleaved caspase-
3) was increased in A549/DDP/miR-146a and SPC-A1/
DDP/miR-146a cells compared swith A549/DDP/NC and
SPC-A1/DDP/NC (Fig. 3d).
Knockdown of CCNJ solely increased the sensitivity of
A549/DDP and SPC-A1/DDP cells to DDP
To explore the individual effect of CCNJ as a novel tar-
get gene of miR-146aon NSCLC DDP resistance, the
expression of CCNJ was down-regulated using RNAi, as
evidenced by RT-qPCR and Western blot assay. As
expected, the mRNA and protein level of CCNJ was sig-
nificantly decreased in A549/DDP/siCCNJ and SPC-A1/
DDP/siCCNJ cells compared with A549/DDP/NC and
SPC-A1/DDP/NC (Fig. 4a). CCK-8 assay was then per-
formed to further assess the role of CCNJ in regulating
growth of A549/DDP and SPC-A1/DPP cells exposed
to DDP. As shown in Fig. 4b, IC50 values of A549/DDP
and SPC-A1/DDP cells transfected with siCCNJ to
DDP were decreased compared with that transfected
with NC (4.85 ± 0.627 μg/ml vs 2.414 ± 0.339 μg/ml and
5.48 ± 0.6409 μg/ml vs 2.80 ± 0.334 μg/ml, respectively
(p < 0.001). Under 1 μg/ml DDP treatment, knockdown of
CCNJ significantly increased the percentage of A549/DDP
SPC-A1/DDP cells in G0/G1 phase compared with
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negative controls (Fig. 4c). In cell apoptosis, the cell apop-
tosis of A549/DDP and SPC-A1/DDP cells which trans-
fected with siCCNJ for 6hand then treat with 1 μg/ml
DDP for 48 h were detected using Annexin V-FITC/PI
flow cytometry (Fig. 4d) and Hoechst staining assay
(Fig. 4e). It was observed that knockdown of CCNJ pro-
moted the cell apoptosis of A549/DDP and SPC-A1/
DDP cells (42.3 vs 18.3% and 29.2 vs 8.7%, respectively
compared with controls. Therefore, knockdown of
CCNJ could also reverse the DDP resistance of resistant
NSCLC cells by inducing cell-cycle arrest in G0/G1
phase and enhancing apoptosis. In addition, transwell
cell migration and Matrigel invasion assay was per-
formed to examine the effect of knockdown of CCNJ
on cell motility ability. The data indicated that knock-
down of siCCNJ markedly inhibited the invasion and
migration of NSCLC resistance cells (Fig. 5a and b).
We also found that the classical drug-resistance-
associated proteins (P-gp, MRP1 and LRP) and P53
were remarkably inhibited and apoptosis-related pro-
tein (cleaved caspase-3) was significantly increased in
A549/DDP/siCCNJ and SPC-A1/DDP/siCCNJ cells
compared with A549/DDP/NC and SPC-A1/DDP/NC
(Fig. 5c). These data further indicated that CCNJ might
(See figure on previous page.)
Fig. 1 Overexpression of miR-146a enhanced the sensitivity to DDP in A549/DDP and SPC-A1/DDP cells. a The mRNA levels of miR-146a in A549/
DDP and SPC-A1/DDP cells stably transfected with miR-146a or NC lentivirus were analyzed by RT-qPCR. b The cell vitality was evaluated by
CCK-8 assay, A549/DDP and SPC-A1/DDP cells stably transfected with miR-146a or NC lentivirus treated with serially diluted DDP. c Representative
data of FACS statistical graph analyses of cell cycle in A549/DDP and SPC-A1/DDP cells stably transfected with miR-146a or NC lentivirus and then
treated with 1 μg/ml DDP for 48 h. d Representative data of FACS and statistical graph analyses of cell apoptosis in A549/DDP and SPC-A1/DDP
cells stably transfected with miR-146a or NC lentivirus and incubated with 1 μg/ml DDP for 48 h. e Representative data of Hoechst staining assay
in A549/DDP and SPC-A1/DDP cells stably transfected with miR-146a or NC lentivirus and then treated with 1 μg/ml DDP for 48 h. All data were
expressed as mean value ± SD from 3 independent experiments. N.S. = no significant, *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 2 Overexpression of miR-146a inhibited the cell invasion and migration in A549/DDP and SPC-A1/DDP cells. a Representative data of cell
invasion assay and statistical graph in A549/DDP and SPC-A1/DDP cells stably transfected with miR-146a or NC lentivirus and treated with 1 μg/
ml DDP for 24 h. b Representative data of cell migration assay and statistical graph in A549/DDP and SPC-A1/DDP cells stably transfected with
miR-146a or NC lentivirus and incubated with 1 μg/ml DDP for 24 h. All data were expressed as mean value ± SD from 3 independent
experiments. ***p < 0.001
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serve as a new target gene for enhancing the chemosen-
sitivity of NSCLC to DDP.
CCNJ was involved in miR-146a induced sensitivity to
DDP in A549/DDP and SPC-A1/DDP cells
To investigate whether CCNJ is involved in miR-146a in-
duced chemoresistance, we performed gain-of-function
and loss-of-function assays in A549/DDP and SPC-A1/
DDP cells. As shown in Fig. 6a, knockdown of CCNJ sig-
nificantly increased the sensitivity to DDP by 2-fold in
A549/DDP/miR-146a (2.71 ± 0.273 μg/ml vs 5.25 ±
0.488 μg/ml) and SPC-A1/DPP/miR-146a cells (2.861 ±
0.3054 μg/ml vs 5.087 ± 0.5673 μg/ml, respectively com-
pared with NC group. Cell cycle analysis was performed
to determine whether there was any cell cycle alteration in
NSCLC cells/DDP/miR-146a after knockdown of CCNJ.
Compared with that of NC-transfected cells, the percent-
age of siCCNJ-transfected AA549/DDP/miR-146a and
SPC-A1/DDP/miR-146a in G0/G1 phase of cell cycle in-
creased from 83.00 to 90.18% and 79.56 to 91.43%, re-
spectively (Fig. 6b). Furthermore, knockdown of CCNJ
could significantly increase cell apoptosis (63.6% vs 38.3%
in A549/DDP cells and 55.7% vs 24.8% in SPC-A1/DDP
cells) compared with individual overexpression of miR-
146a or knockdown of CCNJ (Fig. 6c and d). In addition,
we assessed NSCLC cell invasion and migration through a
transwell assay. As shown in Fig. 7a and b, combined with
knockdown of CCNJ and miR-146a remarkably sup-
pressed the invasion and migration ability induced in
NSCLC resistance cells compared with sole overexpres-
sion of miR-146a or knockdown of CCNJ (p < 0.001).
There results strongly support that knockdown of CCNJ
could enhance the gains of the sensitivity to DDP in miR-
146a-overexpressing A549/DDP and SPC-A1/DDP cells.
Overexpression of miR-146a enhanced the in vivo sensi-
tivity of A549/DDP cells to DDP
To further confirm the effects of miR-146a on the che-
mosensitivity of A549/DDP cells in vivo. Both A549 and
A549/DDP cells stably transfected with miR-146a or NC
were subcutaneously injected into nude mice, followed
by treatment with DDP. As shown in Fig. 8a, the tumors
Fig. 3 CCNJ was a novel target gene of miR-146a. a The binding site of miR-146a and the prediction target genes (CCNJ) through Targetscan web.
b The wild type (CCNJ 3′-UTR-WT) or mutant (CCNJ 3′-UTR-MUT) reporter plasmids were co-transfected into 293T cells with miR-146a or NC lentivirus.
The normalized luciferase activity in the control group was set as relative luciferase activity. c The mRNA levels of CCNJ in A549/DDP and SPC-A1/DDP
cells stably transfected with miR-146a or NC lentivirus and incubated with 1 μg/ml DDP for 48 h were analyzed by RT-qPCR. d The protein levels of
CCNJ, P-gp, MRP1, LRP, P53 and cleaved Caspase-3 were analyzed in A549/DDP and SPC-A1/DDP cells stably transfected with miR-146a or NC lentivirus
by Western blot. All data represented as mean value ± SD from 3 independent experiments. N.S. = no significant, **p < 0.01, ***p < 0.05
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formed from A549/DDP cells stably transfected with
miR-146a grew significantly slowly than those from
empty vector transfected cells, which indicated that up-
regulation of miR-146a inhibited tumor growth. RT-
qPCR analysis found miR-146a was significantly ele-
vated and in tumor tissues formed from miR-146a-
transfected A549//DDP cells than those from controls
(Fig. 8b, p < 0.01). Moreover, up-regulation of miR-146a
led to a significant decrease of CCNJ in tumor tissues, as
determined by RT-qPCR, western blot and IHC, respect-
ively (Fig. 8c, d and e). Furthermore, drug-resistance-
associated proteins (P-gp, MRP1 and LRP) were down-
regulated in A549/DDP/miR-146a compared with NC
group and apoptosis-related protein (cleavedcaspase-3)
were up-regulated by Western blot (Fig. 8d). TUNEL
staining revealed increased apoptotic cells in tumors
generated from miR-146a groups compared with the NC
group (Fig. 8f). These results further demonstrated miR-
146a might play an important role in increasing the che-
mosensitivity of A549/DDP cells to DDP by targeting
CCNJ in vivo.
Discussion
Cisplatin is the most widely used chemotherapy drugs
for the treatment of lung cancer and other tumors [37].
Approximately 1,590,000 lung cancer patients succumb
to the disease every year, 61% of which are primary drug
resistance and 33% have an acquired drug resistance.
Thus, an intense research underlying chemoresistance
should be conducted to further establish better thera-
peutic approaches.
(See figure on previous page.)
Fig. 4 Knockdown of CCNJ enhanced the sensitivity to DDP in A549/DDP and SPC-A1/DDP cells. a The mRNA levels of CCNJ in A549/DDP and
SPC-A1/DDP cells transfected with siCCNJ or NC were analyzed by qRT-PCR. b The cell viability was evaluated by CCK-8 assay, A549/DDP and
SPC-A1/DDP cells transfected with siCCNJ or NC treated with serially diluted DDP. c Representative data of FACS statistical graph analyses of cell
cycle in A549/DDP and SPC-A1/DDP cells transfect with siCCNJ or NC for 6 h and then incubated with 1 μg/ml DDP for 48 h. d Representative
data of FACS and statistical graph analyses of cell apoptosis in A549/DDP and SPC-A1/DDP cells transfected with siCCNJ or NC for 6 h and then
incubated with 1 μg/ml DDP for 48 h. e Representative data of Hoechst staining assay in A549/DDP and SPC-A1/DDP cells transfected with
siCCNJ or NC for 6 hand then incubated with 1 μg/ml DDP for 48 h. All data represented as mean value ± SD from 3 independent experiments.
N.S. = no significant, * p < 0.05, **p < 0.01, ***p < 0.001
Fig. 5 Knockdown of CCNJ inhibited the cell invasion and migration in A549/DDP and SPC-A1/DDP cells. a Representative data of cell invasion
assay and statistical graph in A549/DDP and SPC-A1/DDP cells transfected with siCCNJ or NCfor 6 h and then incubated with 1 μg/ml DDP for
24 h. b Representative data of cell migration assay and statistical graph in A549/DDP and SPC-A1/DDP cells transfected with siCCNJ or NC for 6 h
and then incubated with 1 μg/ml DDP for 24 h. c The protein levels of CCNJ, P-gp, MRP1, LRP, P53 and cleaved Caspase-3were analyzed in A549/
DDP and SPC-A1/DDP cells transfected with siCCNJ or NC for 6 h and then incubated with 1 μg/ml DDP for 48 h by Western blot. All data were
expressed as mean value ± SD from 3 independent experiments. ***p < 0.001
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Fig. 6 (See legend on next page.)
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Currently, more and more studies focus on the re-
search on oncogenes [38], epigenetic dysregulation [39]
and abnormal expression of key genes (especially miR-
NAs) [10, 40] in drug resistance. Moreover, a series of
miRNAs have been proposed as DDP resistance-associated
genes according to miRNA microarray or RT-qPCR array
profiling between A549 and A549/DDP cells [19, 41].
Most of studies have reported that miR-146a acts as
an oncogene involved in tumor genesis and development
[42], but other studies have demonstrated miR-146a
functions as a tumor suppressor [43, 44]. Wu, C. et al.
found that serum levels of miR-146a were potential bio-
markers for the prediction of survival and response to
chemotherapy in NSCLC [45]. Recently, direct targeting
of EGFR by miR-146a was reported in castration-
prostate cancer and HCC cells, leading to significant in-
hibition cell growth, colony formation, and migration
in vitro [46, 47]. These evidences suggest that miR-146a
plays an important role in the development and pro-
gression of cancer.
(See figure on previous page.)
Fig. 6 Overexpression of miR-146a and knockdown of CCNJ further enhanced the sensitivity to DDP in A549/DDP and SPC-A1/DDP cells. a The
cell vitality was evaluated by CCK-8 assay, A549/DDP/miR-146a and SPC-A1/DDP/miR-146a cells transfected with siCCNJ or NC for 6 h and then
treated with serially diluted DDP. b Representative data of FACS statistical graph analyses of cell cycle in A549/DDP/miR-146a and SPC-A1/DDP/
miR-146a cells transfected with siCCNJ or NC for 6 h and then incubated with 1 μg/ml DDP for 48 h. c Representative data of FACS and statistical
graph analyses of cell apoptosis in A549/DDP/miR-146a and SPC-A1/DDP/miR-146a cells transfected with siCCNJ or NC for 6 h and then incubated
with 1 μg/ml DDP for 48 h. d Representative data of Hoechst staining assay inA549/DDP/miR-146a and SPC-A1/DDP/miR-146a cells transfected with
siCCNJ or NC for 6 h and then incubated with 1 μg/ml DDP for 48 h. All data were expressed as mean value ± SD from 3 independent experiments.
*p < 0.05, **p < 0.01, ***p < 0.001
Fig. 7 CCNJ was involved in miR-146a-induced sensitivity to DDP in A549/DDP and SPC-A1/DDP cells. a Representative data of cell invasion assay
and statistical graph in A549/DDP/miR-146a and SPC-A1/DDP/miR-146a cells transfected with siCCNJ or NC for 6 h and then incubated with
1 μg/ml DDP for 24 h. b Representative data of cell migration assay and statistical graph in A549/DDP/miR-146a and SPC-A1/DDP/miR-146a cells
transfected with siCCNJ or NC for 6 h and then incubated with 1 μg/ml DDP for 24 h. All data represented as mean value ± SD from 3 independent
experiments. ***p < 0.001
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To our best knowledge, the role of miR-146a expres-
sion in DDP-resistent NSCLC has not been well docu-
mented. Interestingly, we found that miR-146a was
down-regulated approximately 2-fold in A549/DDP cells,
which attracts us to deeply explore the role of miR-146a
in DDP-resistant NSCLC cells in vitro and vivo. Func-
tional analysis indicated that miR-146a overexpression
could sensitize NSCLC/DDP cells to DDP both in vitro
and vivo by inducing G0/G1 phase arrest, inhibiting cell
motility, and enhancing cell apoptosis. Therefore, we
proposed that miR-146a might act as a chemosensitivity
restorer to DDP in human NSCLC cells.
Further silico analysis showed that CCNJ was the tar-
get gene of miR-146a. The relevance between miR-146a
and CCNJ was subsequently validated by luciferase re-
porter gene assay. As we know, CCNJ is a member of
cyclin family protein that controls cell mitosis involved
in oncogenesis and embryogenesis by forming CDK2/
CCNJ complexes [48, 49]. Venturutti, L. et al. further
suggest that the inhibition of CCNJ could repair the pro-
liferation of breast carcinoma (BC) and gastric carcinoma
(GC) cells in vitro and promote chemosensitive to trastu-
zumab and lapatinib in preclinical BC model [50]. A pre-
vious study also indicated that CCNJ could be a novel
prognostic marker of HCC and acute leukemia (ALM)
[51, 52]. To further investigate the effect of CCNJ in DDP-
resistent NSCLC, both A549/DDP and SPC-A1/DPP cells
were transfected with siCCNJ and then treated with
DDP. As expected, we found that knockdown of CCNJ
increased cell sensitivity to DDP by inducing cell cycle
arrest and cell apoptosis. Notably, we found downregu-
lation of CCNJ could enhance the gains of the
Fig. 8 Overexpression of miR-146a enhanced the sensitivity to DDP in A549/DDP cells in vivo. a Growth curve of tumor volumes and tumor images
of A549, A549/DDP/NC and A549/DDP/miR-146a. Each data point represents the mean ± SD of 8 mice. Quantification of miR-146a (b) and CCNJ mRNA
levels (c) in the transplanted tumor tissues among A549, A549/DDP/NC and A549/DDP/miR-146a by RT-PCR; (d) The quantification of CCNJ,
P-gp, MRP1, LRP, P53 and cleaved caspase-3 in A549, A549/DDP/NC and A549/DDP/miR-146a forming tumor by Western blot. e H&E (upper)
and CCNJ (lower) stained sections of the transplanted tumors by IHC, magnification, 40×, Bars = 50 μm. f The quantification of apoptotic cell
among A549, A549/DDP/NC and A549/DDP/miR-146a tumor tissues by TUNEL assay. All data were represented as mean value ± SD from 3
independent experiments. **p < 0.01, ***p < 0.001
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sensitivity to DDP in miR-146a-overexpressing A549/
DDP and SPC-A1/DDP cells.
There are several cell signaling molecules and path-
ways involved in drug resistance, including the ABC
transporter subfamily B member 1 (ABCB1/MDR1/P-gp)
[53, 54], ABC transporter subfamily C member 1
(ABCC1/MRP-1) [54], and lung resistance-related protein
(LRP) [55]. Consistant with these reports, our results
further demonstrated that miR-146a could downregu-
late drug-resistance-associated proteins (P-gp, MRP1
and LRP) and upregulate the expression of cleaved
caspase-3 in vitro and vivo. However, we found P53, as
a tumor suppressor, presented slightly downregulated
in NSCLC/DDP cells after treated with miR-146a or
siCCNJ, but no obvious change in tumor formed from
A549/DDP cells stably transfected with miR-146a.
These might be ascribed to cell growth status and dif-
ferent types of cells. Collectively, our results revealed
that miR-146a overexpression could obviously increase
the chemosensitivity of NSCLC/DDP cells to DDP by
downregulating drug-resistance-associated proteins.
Conclusions
In summary, we firstly reported miR-146a was downregu-
lated was in DDP-resistant human NSCLC cells (A549/
DDP and SPC-A1/DDP) compared with the sensitive par-
ental cell line A549 and SPC-A1, and further demon-
strated that miR-146a might act as a chemosensitivity
restorer to DDP in human NSCLC cells by targeting CCNJ
and downregulating P-gp, MRP1 and LRP. Based on these
evidences, our experimental data may provide a novel
therapeutic application of targeting the miR-146a/CCNJ
interaction to treat DDP-based regimens-resistant NSCLC.
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